

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the
Investment Company Act of 1940

☐ Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* CARDOZA GEORGE			2. Issuer Name and Ticker or Trading Symbol NEOGENOMICS INC [NEO]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ X Officer (give title below) _____ Other (specify below) _____ President & COO, Lab Ops		
(Last) (First) (Middle) 9490 NEOGENOMICS WAY			3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022					
(Street) FORT MYERS, FL 33912			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned					
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock			Code V	Amount (A) or (D) Price				
Common Stock	03/01/2022		F	503 (1) D \$ 0	244,996	D	Trust by Self	
Common Stock	03/02/2022		F	839 (2) D \$ 0	244,157	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained
in this form are not required to respond unless the form displays
a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	(A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 7.52					(3) 04/28/2022	Common Stock 50,000.00		50,000	D	
Stock Option (Right to Buy)	\$ 8.03					(4) 02/26/2023	Common Stock 192,500.00		192,500	D	
Stock Option (Right to Buy)	\$ 19.60					(5) 03/01/2024	Common Stock 51,459.00		51,459	D	
Stock Option (Right to Buy)	\$ 28.33					(6) 03/02/2027	Common Stock 48,768.00		48,768	D	
Stock Option (Right to Buy)	\$ 53.17					(7) 03/02/2028	Common Stock 35,171.00		35,171	D	

Stock Option (Right to Buy)	\$ 43.95								(8)	07/05/2028	Common Stock	40,502.00		40,502	D	
-----------------------------	----------	--	--	--	--	--	--	--	-----	------------	--------------	-----------	--	--------	---	--

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
CARDOZA GEORGE 9490 NEOGENOMICS WAY FORT MYERS, FL 33912			President & COO, Lab Ops	

Signatures

/s/ Halley E. Gilbert, Attorney-in-Fact		03/03/2022
Signature of Reporting Person		Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2022 vesting of restricted stock.
- (2) Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2022 vesting of restricted stock.
- (3) On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
- (4) On February 26, 2018, Mr. Cardoza was granted 192,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.
- (5) On March 1, 2019, Mr. Cardoza was granted 51,459 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- (6) On March 2, 2020, Mr. Cardoza was granted 48,768 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- (7) On March 2, 2021, Mr. Cardoza was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- (8) On July 5, 2021, Mr. Cardoza was granted 40,502 stock options. These options vest ratably over the first four anniversary dates of the grant date.

Remarks:
Exhibit List:
Exhibit 24 - Limited Power Of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints William Bonello, Halley Gilbert, and Ali Olivo, and each of them individually, with full power of substitution, as the undersigned's true and lawful

(1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and

(2) execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of NeoGenomics, Inc. (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with

(3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute

(4) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally required

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the execution of

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned's holdings

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of January, 2022.

/s/ George Cardoza